Now that talk of a growth stock rally has spread to the pages of The Wall Street Journal, it's time to check in on some of the funds that ought to be benefiting from the shift. Our subject this week is American Century Vista. 

Manager Glenn Fogle, who was recently named as one of Standard & Poor's best, has a history of sticking it to the market and is at it again this year. Morningstar reports that Vista is up 17.5% so far in 2007, nine percentage points better than the S&P 500.

And that's in spite of Fogle's propensity to dance on a hamster wheel. Vista turns over 234% of its portfolio annually. Talk about impressive.

Fogle overcomes the churn by sticking with a strategy that favors fast movers. That's understandable. Fogle and all-star stock pickers like him know that:

How we do it
Of course, not all growth stocks will do. Our weekly hunt is for the next great multibagger. But unlike David Gardner and his team at Motley Fool Rule Breakers, who scour everything from financial statements to trade magazines to clinical reports in their research, we're going to rely on our Motley Fool CAPS investor intelligence database.

Specifically, we're looking for stocks that have earned a five-star rating in CAPS and which are expected to grow their earnings by at least 20% annually over the next five years. Five-star stocks are those that the community, on the whole, believes will outperform the S&P 500.

Let's have the list
Now, with that preamble behind us, here are five more top growth stocks:

Company

No. of CAPS ratings

Bullish CAPS ratings

5-year growth est.

ICAD

(NASDAQ:ICAD)

50

50

35.0%

Smith & Wesson

(NASDAQ:SWHC)

208

196

30.0%

PeopleSupport

(NASDAQ:PSPT)

276

270

25.0%

Alumina

(NYSE:AWC)

21

19

23.4%

Systems Xcellence

(NASDAQ:SXCI)

39

37

20.0%

Source: Motley Fool CAPS, Yahoo! Finance

Bear in mind that this isn't a list of recommendations. Instead, I offer these stocks as candidates for further research. But of these five it's ICAD, which helps digitize the science of radiology for the treatment of cancer, that interests me most. I'll let CAPS investor humpy666 explain the thesis:

Growth potential is incredible. Super product in great demand and is affordable. Advent of partnership with Fujifilm (NASDAQ:FUJI) gives them a huge sales force for free. This one could go to twenty if the stars are right.

Intrigued? Do your own due diligence and then check in with thousands of other investors at CAPS. And, if you'd like, add your own commentary. You'll be helping your fellow Fools and testing your ideas at the same time. Click here to get started now; the service is 100% free.

See you back here next week for five more top growth stocks.

Fool contributor Tim Beyers, who is ranked 6,000 out of more than 29,200 rated CAPS players, is a sucker for growth stocks and a regular contributor to Rule Breakers. Tim didn't own shares in any of the companies mentioned in this article at the time of publication. Tim's portfolio holdings can be found at his Fool profile. His thoughts on growth stocks, Foolishness, and investing in general may be found in his blog. The Motley Fool's disclosure policy is your portfolio's competitive advantage.